SARS-Co-V2 infection in never, former, and current tobacco/nicotine users: a cohort study of 4040 Egyptian healthcare workers.
COVID-19
Cohort
Egypt
Healthcare workers
Nicotine
SARS-co-V2
Smoking
Tobacco
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
28 06 2021
28 06 2021
Historique:
received:
02
04
2021
accepted:
14
06
2021
entrez:
29
6
2021
pubmed:
30
6
2021
medline:
2
7
2021
Statut:
epublish
Résumé
Smoking negatively impacts COVID-19 severity and adverse outcomes. Evidence on whether smoking is associated with SARS-Co-V2 infection and having a positive test is scarce, particularly from low-and middle-income countries, where most of the world's billion smokers live. The inconsistency in relevant findings calls for study designs and analyses to account for possible confounders including background characteristics and pre-existing co-morbidities, to disentangle the specific effect of smoking. In healthcare workers (HCWs) the frequency of exposure to COVID-19 cases adds another layer of risk that was not factored in previous studies. We examined the association of HCWs' tobacco/nicotine use (never, former, and current use) with having a positive SARS-Co-V2 test result and symptoms suggestive of infection, accounting for demographics, exposures, and co-morbidities. A prospective cohort study of 4040 healthcare workers with baseline and follow-up screening took place during April-June 2020 in 12 healthcare facilities in Cairo, Egypt. Data on demographics, tobacco/nicotine use (manufactured or roll-your-own cigarettes, waterpipe tobacco, and electronic devices), co-morbidities, symptoms, exposures, and SARS-Co-V2 investigations were analyzed. Multinomial and multivariable logistic regression analyses were performed. Overall, 270/4040 (6.7, 95%CI: 5.9-7.5) had positive SARS-CoV-2 tests, 479 (11.9%) were current and 79 (2.0%) were former tobacco/nicotine users. The proportion of positive tests was 7.0% (243/3482, 95%CI: 6.1-7.8) among never, 5.1% (4/79, 95%CI: 0.1-10.0) among former, and 4.8% (23/479, 95%CI: 2.9-6.7) among current users. HCWs' SARS-CoV-2 test results did not vary significantly by single/multiple or daily/non-daily tobacco/nicotine use. Compared to never users, former users were more likely to self-report a pre-existing medical condition (OR This is the first report on this association from low- and middle-income countries with high tobacco/nicotine use prevalence. In this HCW cohort, having a positive SARS-CoV-2 test was not associated with tobacco/nicotine use after accounting for demographics, exposures, and co-morbidities. Additional population-based studies could use such preliminary evidence to investigate this controversial association.
Sections du résumé
BACKGROUND
Smoking negatively impacts COVID-19 severity and adverse outcomes. Evidence on whether smoking is associated with SARS-Co-V2 infection and having a positive test is scarce, particularly from low-and middle-income countries, where most of the world's billion smokers live. The inconsistency in relevant findings calls for study designs and analyses to account for possible confounders including background characteristics and pre-existing co-morbidities, to disentangle the specific effect of smoking. In healthcare workers (HCWs) the frequency of exposure to COVID-19 cases adds another layer of risk that was not factored in previous studies. We examined the association of HCWs' tobacco/nicotine use (never, former, and current use) with having a positive SARS-Co-V2 test result and symptoms suggestive of infection, accounting for demographics, exposures, and co-morbidities.
METHODS
A prospective cohort study of 4040 healthcare workers with baseline and follow-up screening took place during April-June 2020 in 12 healthcare facilities in Cairo, Egypt. Data on demographics, tobacco/nicotine use (manufactured or roll-your-own cigarettes, waterpipe tobacco, and electronic devices), co-morbidities, symptoms, exposures, and SARS-Co-V2 investigations were analyzed. Multinomial and multivariable logistic regression analyses were performed.
RESULTS
Overall, 270/4040 (6.7, 95%CI: 5.9-7.5) had positive SARS-CoV-2 tests, 479 (11.9%) were current and 79 (2.0%) were former tobacco/nicotine users. The proportion of positive tests was 7.0% (243/3482, 95%CI: 6.1-7.8) among never, 5.1% (4/79, 95%CI: 0.1-10.0) among former, and 4.8% (23/479, 95%CI: 2.9-6.7) among current users. HCWs' SARS-CoV-2 test results did not vary significantly by single/multiple or daily/non-daily tobacco/nicotine use. Compared to never users, former users were more likely to self-report a pre-existing medical condition (OR
CONCLUSIONS
This is the first report on this association from low- and middle-income countries with high tobacco/nicotine use prevalence. In this HCW cohort, having a positive SARS-CoV-2 test was not associated with tobacco/nicotine use after accounting for demographics, exposures, and co-morbidities. Additional population-based studies could use such preliminary evidence to investigate this controversial association.
Identifiants
pubmed: 34182960
doi: 10.1186/s12889-021-11290-x
pii: 10.1186/s12889-021-11290-x
pmc: PMC8238378
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1243Références
Addiction. 2021 Jun;116(6):1319-1368
pubmed: 33007104
AMIA Annu Symp Proc. 2018 Apr 16;2017:1392-1400
pubmed: 29854208
J Clin Virol. 2020 Jul;128:104412
pubmed: 32416600
Arch Environ Occup Health. 2021;76(1):37-44
pubmed: 32469291
Tob Induc Dis. 2020 Jul 03;18:58
pubmed: 32641924
Int J Infect Dis. 2021 Mar;104:534-542
pubmed: 33484863
J Clin Med. 2020 Mar 20;9(3):
pubmed: 32244852
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
Lancet. 2016 Oct 8;388(10053):1659-1724
pubmed: 27733284
Ann N Y Acad Sci. 2012 Feb;1248:107-23
pubmed: 22092035
Tob Control. 2020 Aug 21;:
pubmed: 32826387
Int J Epidemiol. 2021 Mar 3;50(1):50-61
pubmed: 33094320
Ther Adv Chronic Dis. 2020 Jun 25;11:2040622320935765
pubmed: 32637059
Am J Physiol Regul Integr Comp Physiol. 2018 Nov 1;315(5):R895-R906
pubmed: 30088946
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
Thorax. 2021 Jul;76(7):714-722
pubmed: 33402392
Respir Med. 2012 Dec;106 Suppl 2:S25-32
pubmed: 23290701
Tob Induc Dis. 2020 Nov 02;18:89
pubmed: 33149732
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651